Pfizer’s experimental RSV vaccine under investigation for causing rare nervous system disorder
03/08/2024 / By Ava Grace
Last year, an advisory panel for the Centers for Disease Control and Prevention (CDC) recommended Americans aged 60 and older get a single dose of a vaccine for the respiratory syncytial virus (RSV). Two RSV vaccine options were made available, one by Pfizer and the other by GSK.
Now, Pfizer’s vaccine is under investigation for causing the rare nervous system disorder Guillain-Barre.
CDC officials said they were investigating more than 20 cases of Guillain-Barre syndrome (GBS), a rare illness in which a person’s immune system damages its own nerve cells, causing muscle weakness and paralysis, allegedly caused by the RSV vaccines.
“Serious neurologic conditions, including [GBS], have been reported after RSV vaccination in clinical trials of older adults. It is unclear whether the vaccine caused these events,” the CDC writes.
An estimated 3,000 to 6,000 people develop GBS in the United States each year, and it’s more commonly seen in older people, according to the CDC. (Related: RSV introduced into population by polio vaccines; now Pfizer’s RSV vaccines risk harming, killing people.)
Most people fully recover from the syndrome, but some have permanent nerve damage. Guillain-Barre can occur in people after they are infected with a virus, but in some instances, cases have been linked to vaccinations.
RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms but it can be dangerous for infants and the elderly. The CDC claims RSV is responsible for an estimated 177,000 hospitalizations and 14,000 deaths per year among adults 65 and older.
Two Guillain-Barre cases caused by Pfizer’s RSV vaccine confirmed
Two people who received Pfizer’s RSV vaccine during a clinical trial were later diagnosed with GBS, and the U.S. Food and Drug Administration (FDA) has asked Pfizer to conduct a safety study.
The pharma giant claims its RSV vaccine, Abrysvo, protects older adults from RSV. Just one dose is supposedly 77.8 percent effective against lower respiratory tract disease associated with RSV.
The two confirmed GBS cases were adults in their 60s who participated in Pfizer’s Phase 3 clinical trial for Abrysvo. One person’s illness had completely resolved after three months, and another was improving after six months.
“Given the temporal association and biological plausibility, FDA agrees with the assessments of the investigators that these events were possibly related to study vaccine… Therefore, [GBS] is being considered an important potential risk,” wrote the FDA in the documents, which were released ahead of a meeting with its vaccine advisers, the Vaccines and Related Biological Products Advisory Committee, to discuss granting approval to Abrysvo.
In the document, Pfizer defended itself by claiming that the cases have other possible explanations and that its vaccine is a “well-tolerated and safe vaccine, with a benefit-to-risk ratio that is favorable.”
VaccineDamage.news has more information on dangerous and experimental new vaccinations.
Watch this clip from “Faithful Freedom with Teryn Gregson” on Red Voice Media discussing how the RSV vaccines are the new Wuhan coronavirus (COVID-19) vaccines.
This video is from the Red Voice Media channel on Brighteon.com.
More related stories:
FDA panel unanimously supports new RSV antibody drug for infants.
Largest-ever COVID jab study ties popular injections to serious health risks.
Watch out for the ELECTION VARIANT and Covid Booster Syndrome.
Cases of white lung syndrome reported in the U.S. and China.
Sources include:
Submit a correction >>
Tagged Under:
This article may contain statements that reflect the opinion of the author
RECENT NEWS & ARTICLES
